Effectiveness of swapping to ustekinumab after vedolizumab failure in patients with multi-refractory Crohn's disease. Issue 2 (February 2023)

• Record Type: Journal Article
• Authors: Melotti, Laura; Dussias, Nikolas Konstantine; Salice, Marco; Calabrese, Carlo; Baldoni, Monia; Scaioli, Eleonora; Belluzzi, Andrea; Mazzotta, Elena; Gionchetti, Paolo; Rizzello, Fernando
• Is Part Of: Digestive and liver disease. Volume 55:Issue 2(2023)
• Page Start: 230
• Page End: 234
• Publication Date: 2023-02
• Subjects: Anti-TNF failure -- Clinical remission -- Endoscopic activity -- Third-line biologics; Digestive organs -- Diseases -- Periodicals; Liver -- Diseases -- Periodicals; 616.33005
• DOI: 10.1016/j.dld.2022.06.029
• Languages: English
• ISSNs: 1590-8658

Abstract

Abstract: Background: Ustekinumab (UST) and vedolizumab (VDZ) are biologic therapies for moderate-to-severe Crohn's disease (CD) in patients who failed or had contraindication to anti-TNF treatment. Aims: To evaluate ustekinumab efficacy as third-line treatment after swapping from VDZ for failure. Methods: We conducted a monocentric, retrospective, observational study where CD patients were followed for 12 months from the beginning of UST therapy. We assessed clinical activity (HBI) and laboratory markers (CRP) at the initiation of UST therapy (T0) and after 2(T2), 6(T6) and 12(T12) months. Endoscopic activity was recorded at T0 and T12. We registered data regarding their clinical history and previous biologic treatments. Steroid-free clinical remission was defined as HBI ≤ 4 without need for steroids. Clinical response was defined as HBI reduction of at least three points or the suspension of steroids. Results: 27 CD patients treated with UST after VDZ failure had a minimum follow up of 12 months and were included. All patients had previously been treated with anti-TNF agents. After 12 months, steroid-free clinical remission was evident in 15 (55.5%) patients, 5 (18.5%) had clinical response, while 7 (26%) had suspended for failure or persisted on treatment after optimization. Conclusions: Ustekinumab should be considered as third-line biologic treatment in multi-refractory CD patients.